Streetbeat News

FWBI

First Wave BioPharma Inc

https://www.azurrx.com/

CEO

James Sapirstein

Employees

12

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.

Open

2.93

Mkt cap

6M

Volume

56K

High

3.04

P/E Ratio

-0.06

52-wk high

60.00

Low

2.84

Div yield

N/A

52-wk low

2.33

First Wave BioPharma Inc (FWBI) plans to acquire ImmunogenX in an all-stock transaction to enhance its GI disease pipeline. The deal is expected to close in H1 2024. FWBI's CEO will remain, with ImmunogenX's CEO becoming CMO. FWBI anticipates non-dilutive funding from a strategic pharma company for latiglutenase's U.S. rights and investor commitments for development post-closing. Latiglutenase, for celiac disease, is set for Phase 3 trials in H2 2024. FWBI also licensed Capeserod from Sanofi SA (SNY) for GI uses and enacted a 1-for-20 reverse stock split.

Portfolio Pulse from Vandana Singh

December 18, 2023 | 11:00 am

First Wave BioPharma has announced a 1-for-20 reverse stock split, approved by its Board of Directors, to take effect soon. This action is typically aimed at boosting the stock's market price and ensuring compliance with minimum bid price requirements for continued listing on stock exchanges.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 2:19 pm

In Tuesday's after-market session, several healthcare stocks experienced significant movements. Reshape Lifesciences (RSLS) saw a 58.2% increase, while NightHawk Biosciences (NHWK) rose by 12.9%. Minerva Surgical (UTRS) increased by 9.99%, Yield10 Bioscience (YTEN) by 9.5%, Inhibikase Therapeutics (IKT) by 8.33%, and Senti Biosciences (SNTI) by 8.31%. Conversely, LumiraDx (LMDX) fell by 7.7%, Fate Therapeutics (FATE) by 6.67%, Sera Prognostics (SERA) by 5.51%, Gracell Biotechnologies (GRCL) by 5.0%, First Wave BioPharma (FWBI) by 4.84%, and Hepion Pharmaceuticals (HEPA) by 4.82%.

Portfolio Pulse from Benzinga Insights

December 12, 2023 | 9:31 pm

The article discusses notable value stocks in the healthcare sector, highlighting their low price-to-earnings (P/E) multiples, which suggest they may be undervalued. The stocks mentioned are Cross Country Healthcare (CCRN), Nuwellis (NUWE), First Wave BioPharma (FWBI), Voyager Therapeutics (VYGR), and Panbela Therapeutics (PBLA). The article also provides recent earnings per share data for these companies, indicating their financial performance.

Portfolio Pulse from Benzinga Insights

December 11, 2023 | 2:43 pm

Benzinga Insights has identified notable value stocks in the healthcare sector based on low P/E multiples. First Wave BioPharma (FWBI), Kiora Pharmaceuticals (KPRX), TherapeuticsMD (TXMD), Voyager Therapeutics (VYGR), and Organon (OGN) are highlighted as undervalued. FWBI, KPRX, and VYGR reported decreased earnings per share in their latest quarters, while TXMD saw an increase, and OGN experienced a decrease but also reported a higher dividend yield.

Portfolio Pulse from Benzinga Insights

November 27, 2023 | 2:43 pm

In Thursday's pre-market session, several healthcare stocks experienced significant movements. Heart Test Laboratories, NeuroOne Medical Tech, PaxMedica, Blue Water Biotech, OpGen, and Avinger saw their stocks rise, with increases ranging from 10.63% to 22.4%. On the other hand, Alterity Therapeutics, UpHealth, First Wave BioPharma, SILO Pharma, TRACON Pharma, and Altamira Therapeutics faced declines between 10.3% and 19.8%. Market caps for these companies vary, with the smallest at $2.6 million and the largest at $34.8 million.

Portfolio Pulse from Benzinga Insights

November 23, 2023 | 1:05 pm

First Wave Bio has been granted Australian Patent Number 2016315852 for methods and compositions for treating conditions associated with abnormal inflammatory responses.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 5:19 pm

Benzinga Insights has identified five value stocks in the healthcare sector based on quantified analysis. These include OraSure Technologies (P/E: 9.83), Assertio Holdings (P/E: 1.47), CalciMedica (P/E: 0.0), Quoin Pharmaceuticals (P/E: 0.01), and First Wave BioPharma (P/E: 0.0). The Q2 earnings per share for these companies have shown mixed results compared to Q1.

Portfolio Pulse from Benzinga Insights

October 09, 2023 | 2:44 pm

Several healthcare stocks experienced significant movement in Friday's after-market session. ContraFect, Exagen, Pasithea Therapeutics, Talaris Therapeutics, Renalytix, and GRI Bio saw their stocks rise, while Addex Therapeutics, Dyadic International, Sunshine Biopharma, Senti Biosciences, First Wave BioPharma, and Salarius Pharmaceuticals experienced a decline.

Portfolio Pulse from Benzinga Insights

October 06, 2023 | 9:31 pm

The article discusses value stocks in the healthcare sector, which are traditionally undervalued. The companies mentioned include First Wave BioPharma, Arcturus Therapeutics, CalciMedica, POINT Biopharma Global, and Innoviva. All these companies have seen a decrease in their earnings per share recently.

Portfolio Pulse from Benzinga Insights

October 02, 2023 | 2:43 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.